.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018.
., although most have plans that will adequately improve air quality.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
.
.